Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok then $10.00, this is going to go up fast an firious at some point $$$$$
$$5 is not impossible
BMRA: Monster THANKS, Admiral H-C, Dude --- for the heads-up, Bro!!! (LOVE this stuff!!!)
We bought this today, loaded! This company may soar to the moon! $$$$$$
BMRA: Looks good!!
Holding tight after market. Low issues shared could potentially be a 10 bagger
BMRA: Heck, anything affiliated with the UAE over there is gonna get big attention!!
great dip now 0.65
news was good today
Nice volume looks liken.67 will hold for next round but Caution as always
See if it holds at least .67 can do another round doesn't hold then wait for .50 to .53
bmra....................................https://stockcharts.com/h-sc/ui?s=bmra&p=W&b=5&g=0&id=p86431144783
pretty good news release id say
BMRA: But ya banked some coin, Bro!! (I've been takin' YOUR sage advice for months now, on HOW to play this Wall Street CASINO.)
I still DO like their NEWS here today. (They got that HALF-MILE-HIGH building over there!!)
https://en.wikipedia.org/wiki/Burj_Khalifa
////////////////////////////////////////////////////////////////////////////////////////////
Took 80% off $1.15- $1.18 unless followed through will be all out average .88 so $.95 out
holy shi_ ..... LET'S GOOOOO
looking good breakout of $1.29 solid and off to $2 land should be a done deal
BMRA; Excuse me for a minute, my PROSTATE wants to take a PISS again!!!! (And my "Big-Gulp-Coffee" from 7/11 15-minutes ago didn't help it EITHER!!!)
coming $2+ today still ?
It looks as though it will open back up in the $1.32 range
BMRA: My BLADDER woke me up!!! (Who says that???)
Yes lots of revenues potential immediately see a resistance zone all the way up $2.75 to $2.96 if they really let the goose loose. See what happens US contracts on the way
Insiders loaded back on 12/17 with millions of shares @ $0.31. They knew this was gonna happen. https://www.otcmarkets.com/stock/BMRA/disclosure
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer
- Prostate Cancer: The Second Most Common Cancer in Men Globally
IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab Emirates Ministry of Health and Prevention (MOHAP).
The Fortel® PSA Screening Test is a user-friendly diagnostic tool that provides accurate results in just 10 minutes using a simple finger-prick blood sample. By measuring elevated PSA levels, a recognized early marker of prostate disease, the test can enable early detection of prostate cancer and other prostate-related conditions. This rapid and accessible approach aims to enhance proactive health management, reduce the burden on healthcare systems, and improve patient outcomes.
Strategic Expansion in the Middle East
This milestone approval is part of Biomerica’s strategic initiative to expand its footprint in the Middle East, where prostate cancer is increasingly recognized as a critical public health concern. Building on its success in the region with the EZ Detect Colon Disease At-Home Screening Test, which received government insurance reimbursement in Dubai, Biomerica is working to replicating this achievement with the Fortel® PSA test. The Company has established partnerships with leading distributors and secured key regulatory approvals to make early cancer detection more accessible to patients in the region.
Proven Performance
The Fortel® PSA test has demonstrated outstanding performance in rigorous evaluations:
A study reported 100% sensitivity, 95% specificity, and 97.5% accuracy, aligning with laboratory reference methods.
Research conducted at the Faculty of Medicine, Ain Shams University in Egypt, further validated the test’s effectiveness, achieving 97.2% sensitivity, 96.2% specificity, and 96.7% accuracy.
These results highlight the Fortel® PSA test as a reliable and efficient tool for early detection.
The Growing Global and Regional Impact of Prostate Cancer
Prostate cancer is the second most common cancer among men worldwide, with 1.4 million new cases diagnosed and 375,000 deaths reported globally in 20201. Alarmingly, one new case is diagnosed every two minutes2. While extensive research and advancements in early detection have been made in Europe and North America, prostate cancer has become increasingly recognized as a significant public health challenge in the Middle East. The disease varies in prevalence and severity across different regions, age groups, ethnicities, and races and there remains a gap in comprehensive studies within the Middle East3.
Looking Ahead: Expanding Access to Life-Saving Diagnostics
Biomerica is reinforcing its commitment to expanding access to innovative diagnostic solutions in the Middle East. The company’s vision remains focused on providing affordable, accurate, and accessible tools to aid in the early detection and treatment of critical diseases like prostate cancer.
https://uroweb.org/guidelines/prostate-cancer/chapter/epidemiology-and-aetiology%E2%80%8B
https://zerocancer.org/about-prostate-cancer/facts-statistics
Mutlay Sayan et al. Prostate Cancer Awareness in the Middle East: A Cross-Sectional International Study. JCO Glob Oncol 10, e2400171(2024).
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the Company’s current and future sales, revenues, overhead, expenses, cost of goods, operations and earnings, efficacy of the Company’s products and tests, FDA and/or international regulatory authorization for the Company’s products to be marketed and sold, including the Fortel PSA product, and the Company’s other current and future products, the possible expansion in to other markets, uniqueness of the Company’s products, accuracy of the Company’s tests and products, pricing of the Company’s test kits, domestic and/or international market adoption and acceptance and demand for the Company’s products, future use of the Company's products by physicians to treat their patients, potential revenues from the sale of current or future products. Such forward-looking information involves impo
Yes my bad zone it's in now is .74 to $1.29 let the goose loose.
.83 resistance see if .53 to .57 new support
Early morning jackpot prostate news .80 +'120%
BMRA: And MONSTER news over in the ARABIC world for this PUPPY!!!
BMRA.............https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783
They vote on a RS next Friday the 13th - not a good omen IMO
BMRA...................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783
Most volume in a year .. potential here?
BMRA....................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783
BMRA...........................................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
BMRA.................................https://stockcharts.com/h-sc/ui?s=BMRA&p=W&b=5&g=0&id=p86431144783
Followers
|
40
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
585
|
Created
|
04/18/07
|
Type
|
Free
|
Moderators |
Trading on the OTC-QB as BMRA.
http://www.biomerica.com/index.asp
Biomerica, Inc. is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices ) and in hospital and clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica's primary focus is on products for Diabetes, Gastrointestinal Disease and esoteric testing.
Biomerica is dedicated to exploring new distributorship opportunities to bring our innovative products to the marketplace. Interested parties may contact us at info@biomerica.com.
Please note the new address for our Headquarters:
17571 Von Karman Avenue
Irvine, CA 92614 USA
Tel: 949-645-2111
Fax: 949-553-1231
Since 1971, Biomerica has developed, manufactured, and distributed medical diagnostic products for the early detection and monitoring of chronic diseases and certain medical conditions.
The Company's test kits and devices are sold in three markets:
• Clinical laboratories
• Physician's offices
• Over-the-counter (pharmacies)
Biomerica is proud of its history of product innovation spanning more than three decades in several major clinical areas. It was the first Company to manufacture and market tests for:
• Myoglobin (Cardiac)
• H. Pylori (Digestive Disease)
• Histamine (Allergy)
• Self test for Colon Disease (Digestive)
• Early detection of Diabetes (Diabetes).
All of our products are CE marked for European sales and manufactured under EN ISO 13485:2003 certification.
http://www.biomerica.com/products/index.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |